UroGen Pharma Ltd. Ordinary Shares (URGN) is a publicly traded Healthcare sector company. As of August 24, 2026, URGN trades at $46.15 with a market cap of $2.29B and a P/E ratio of -23.53. URGN moved -1.56% today. Year to date, URGN is +97.10%; over the trailing twelve months it is +137.45%. Its 52-week range spans $3.42 to $50.81. Analyst consensus is strong buy with an average price target of $60.20. Rallies surfaces URGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for URGN, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $46.15 |
| Market Cap | $2.29B |
| P/E Ratio | -23.53 |
| EPS | $-1.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $50.81 |
| 52-Week Low | $3.42 |
| Volume | 707.63K |
| Avg Volume | 0 |
| Revenue (TTM) | $188.73M |
| Net Income | $-97.64M |
| Gross Margin | 90.84% |
5 analysts cover URGN: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $60.20.